Increased soluble urokinase-type plasminogen activator receptor (suPAR) levels in plasma of suicide attempters

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Ventorp, Filip ^a   Gustafsson, Anna ^b   Träskman Bendz, Lil ^a   Westrin, Åsa ^a   Ljunggren, Lennart ^b  

^a LUND UNIVERSITY   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; UROKINASE RECEPTOR; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MALE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SENSIBILITY; SUICIDE ATTEMPT; BLOOD; METABOLISM; MIDDLE AGED; PSYCHOLOGY; SOLUBILITY; YOUNG ADULT;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; REACTIVE OXYGEN SPECIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SOLUBILITY; SUICIDE, ATTEMPTED; YOUNG ADULT;

EID: 84948654411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140052     Document Type: Article

References (41)

1. American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013. xliv, 947 p. p.
2. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without mental health. Lancet. 2007; 370(9590):859-77. doi: 10.1016/S0140-6736(07)61238-0 PMID: 17804063.
3. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. The journal of mental health policy and economics. 2006; 9(2):87-98. PMID: 17007486.
4. Coryell W, Young EA. Clinical predictors of suicide in primary major depressive disorder. J Clin Psychiatry. 2005; 66(4):412-7. Epub 2005/04/09. PMID: 15816781.
5. Bauer M, Monz BU, Montejo AL, Quail D, Dantchev N, Demyttenaere K, et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. European psychiatry: the journal of the Association of European Psychiatrists. 2008; 23(1):66-73. doi: 10.1016/j.eurpsy.2007.11.001 PMID: 18164600.
6. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. The British journal of psychiatry: the journal of mental science. 2001; 178:234-41. PMID: 11230034.
7. Howland RH. Sequenced Treatment Alternatives to Relieve Depression (STAR∗D). Part 2: Study outcomes. Journal of psychosocial nursing and mental health services. 2008; 46(10):21-4. PMID: 18935932.
8. Smith RS. The macrophage theory of depression. Medical hypotheses. 1991; 35(4):298-306. PMID: 1943879.
9. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological psychiatry. 2009; 65(9):732-41. doi: 10.1016/j.biopsych. 2008.11.029 PMID: 19150053; PubMed Central PMCID: PMC2680424.
10. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biological psychiatry. 2010; 67(5):446-57. doi: 10.1016/j.biopsych.2009.09.033 PMID: 20015486.
11. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. Journal of affective disorders. 2004; 82(2):175-90. doi: 10.1016/j.jad.2004.04.002 PMID: 15488246.
12. Halaris A, Leonard BE. Inflammation in psychiatry. Basel: Karger; 2013. viii, 208 p. p.
13. Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K, et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta psychiatrica Scandinavica. 2008; 117(3):198-206. doi: 10.1111/j.1600-0447.2007.01128.x PMID: 18081924; PubMed Central PMCID: PMC2612100.
14. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. Journal of psychiatric research. 2008; 42(2):151-7. Epub 2006/12/19. doi: 10.1016/j.jpsychires.2006. 10.013 PMID: 17174336.
15. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological psychiatry. 2009; 66(3):287-92. Epub 2009/03/10. doi: 10.1016/j.biopsych.2009.01.030 PMID: 19268915.
16. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain, behavior, and immunity. 2011; 25(2):335-9. Epub 2010/10/19. doi: 10.1016/j.bbi.2010.10.010 PMID: 20951793.
17. Raison CL, Miller AH. Do cytokines really sing the blues? Cerebrum: the Dana forum on brain science. 2013; 2013:10. PMID: 24116267; PubMed Central PMCID: PMC3788165.
18. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et al. The cyclooxygenase- 2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular psychiatry. 2006; 11(7):680-4. doi: 10.1038/sj.mp.4001805 PMID: 16491133.
19. Muller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatria Danubina. 2013; 25(3):292-8. PMID: 24048400.
20. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol. 2002; 168(7):3507-11. PMID: 11907112.
21. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, et al. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest. 1996; 97(8):1818-26. doi: 10.1172/JCI118611 PMID: 8621764; PubMed Central PMCID: PMC507249.
22. Wrotek A, Jackowska T, Pawlik K. Soluble Urokinase Plasminogen Activator Receptor: An Indicator of Pneumonia Severity in Children. Advances in experimental medicine and biology. 2014. doi: 10.1007/ 5584-2014-40 PMID: 25315615.
23. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Critical care. 2011; 15(1):R63. doi: 10.1186/cc10037 PMID: 21324198; PubMed Central PMCID: PMC3221996.
24. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Disease markers. 2009; 27 (3):157-72. doi: 10.3233/DMA-2009-0657 PMID: 19893210; PubMed Central PMCID: PMC3835059.
25. Thavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. Journal of immunological methods. 1992; 153(1-2):115-24. PMID: 1381403.
26. Niwa Y, Akamatsu H, Sumi H, Ozaki Y, Abe A. Evidence for degradation of cytokines in the serum of patients with atopic dermatitis by calcium-dependent protease. Archives of dermatological research. 2000; 292(8):391-6. PMID: 10994773.
27. Lyngbaek S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. International journal of cardiology. 2013; 167(3):781-5. doi: 10.1016/j.ijcard.2012.03.040 PMID: 22459389.
28. Haastrup E, Grau K, Eugen-Olsen J, Thorball C, Kessing LV, Ullum H. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PloS one. 2014; 9(10):e110555. doi: 10. 1371/journal.pone.0110555 PMID: 25329298; PubMed Central PMCID: PMC4203805.
29. Bienvenu J, Monneret G, Fabien N, Revillard JP. The clinical usefulness of the measurement of cytokines. Clinical chemistry and laboratory medicine: CCLM / FESCC. 2000; 38(4):267-85. doi: 10.1515/ CCLM.2000.040 PMID: 10928646.
30. Pal M, Febbraio MA, Whitham M. From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. Immunology and cell biology. 2014; 92(4):331-9. doi: 10.1038/icb.2014.16 PMID: 24751614.
31. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et biophysica acta. 2011; 1813(5):878-88. doi: 10.1016/j.bbamcr. 2011.01.034 PMID: 21296109.
32. Masli S, Turpie B. Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells. Immunology. 2009; 127(1):62-72. doi: 10.1111/j.1365-2567.2008.02933.x PMID: 18795974; PubMed Central PMCID: PMC2678182.
33. Petrovsky N. Temporal regulation of the human immune system. Expert review of clinical immunology. 2005; 1(3):379-83. doi: 10.1586/1744666X.1.3.379 PMID: 20476989.
34. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. Journal of psychiatric research. 1999; 33(5):407-18. PMID: 10504009.
35. Himmerich H, Berthold-Losleben M, Pollmacher T. [The relevance of the TNF-alpha system in psychiatric disorders]. Fortschritte der Neurologie-Psychiatrie. 2009; 77(6):334-45. doi: 10.1055/s-0028- 1109420 PMID: 19415585.
36. Nielsen J, Roge R, Pristed SG, Viuff AG, Ullum H, Thorner LW, et al. Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia. Schizophr Bull. 2015; 41(3):764-71. doi: 10.1093/schbul/sbu118 PMID: 25154621; PubMed Central PMCID: PMC4393680.
37. Schizophrenia Psychiatric Genome-Wide Association Study C. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011; 43(10):969-76. doi: 10.1038/ng.940 PMID: 21926974; PubMed Central PMCID: PMC3303194.
38. Gibney SM, Drexhage HA. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol. 2013; 8(4):900-20. doi: 10.1007/s11481-013-9462-8 PMID: 23645137.
39. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological psychiatry. 2011; 70(7):663-71. doi: 10. 1016/j.biopsych.2011.04.013 PMID: 21641581; PubMed Central PMCID: PMC4071300.
40. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem. 2006; 52(7):1284-93. doi: 10.1373/clinchem.2006.067595 PMID: 16690735.
41. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010; 268(3):296-308. doi: 10.1111/j.1365-2796. 2010.02252.x PMID: 20561148.